Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade PMID 42321916
View analysis →A grade PMID 42690647
View analysis →A grade PMID 42372741
View analysis →A grade PMID 42216567
View analysis →A grade PMID 41916649
View analysis →A grade PMID 42382416
View analysis →A grade PMID 42150584
View analysis →B grade PMID 42748428
View analysis →A grade PMID 41756844
View analysis →A grade PMID 42765973
View analysis →A grade PMID 42362103
View analysis →A grade PMID 42101908
View analysis →Using accelerator and nozzle modeling, phantom analysis, and a sample pediatric central nervous system cancer plan, the study reports that smaller proton spot sizes—and, less strongly, narrower energy spreads—improved organ-at-risk sparing while maintaining comparable target coverage.
The supplied evidence supports a dosimetric planning hypothesis that a prospective dielectric wall accelerator configured for an approximately 1 mm lateral spot size and 0.05%–0.5% energy spread could reduce normal-tissue dose in pediatric proton therapy; any resulting reduction in toxicity or improvement in clinical outcomes remains an untested inference.
In a retrospective cohort of 146 children with B-ALL treated in Southern Mexico, 5-year overall and event-free survival were 50% and 37.6%, respectively, with treatment non-adherence associated with poorer survival and indigenous status independently associated with increased relapse hazard.
The evidence establishes prognostic associations rather than an intervention effect; it supports the hypothesis that targeted adherence and socioeconomic-support strategies for vulnerable families, particularly indigenous patients, could reduce relapse and improve survival, but this requires prospective testing.
In the St Jude Lifetime Cohort, 94 of 5,229 childhood cancer survivors experienced late venous thromboembolism, with higher prevalence than community controls and adjusted associations with chest radiation, abdominal radiation, and sex hormone use.
The evidence supports using prior radiation exposure and sex hormone use as candidate factors for late-VTE risk assessment in childhood cancer survivors; it is an untested inference that risk-adapted monitoring, modification of hormone exposure, or prophylaxis would reduce VTE events.
In MG63 and Saos2 osteosarcoma cells, astragaloside IV reduced viability and altered ferroptosis-related, oxidative-stress, iron-metabolism, and JAK2/STAT3 markers, with effects attenuated by ferroptosis inhibition or TFRC knockdown.
The reported cell-line evidence supports the hypothesis that astragaloside IV exerts antitumor activity partly through TFRC-dependent ferroptosis accompanied by JAK2/STAT3 inhibition; whether this can produce a safe, selective, and clinically achievable therapeutic effect in osteosarcoma remains an untested inference.
In a single-center retrospective cohort of 57 children with chronic non-bacterial osteomyelitis, 22 received off-label zoledronic acid, with reported clinical improvement in 77%, radiological improvement in 8 of 10 patients with paired whole-body MRI, and no serious adverse events.
The cohort provides preliminary evidence that intermittently dosed zoledronic acid may improve clinical and MRI manifestations of severe or refractory pediatric chronic non-bacterial osteomyelitis; whether it is superior to other treatments or improves long-term outcomes remains an inference requiring controlled prospective study.
In this pediatric cross-sectional case-control study, hypothalamic obesity and common obesity showed broadly similar appetite-related hormonal profiles, while lower αMSH and ghrelin concentrations were independently associated with faster BMI increase.
The observed inverse association between αMSH concentration and BMI gain supports investigating impaired melanocortin signaling as a contributor to hypothalamic obesity; αMSH-pathway augmentation is a hypothesis for future testing, not an intervention shown here to be effective or safe.
In a retrospective single-centre cohort of 60 children undergoing proximal femoral tumour resection and endoprosthetic reconstruction, implant failure patterns differed by age, adolescent THA had better revision-free survival than adolescent hemiarthroplasty, and conversion of failed hemiarthroplasty to THA was generally durable despite early dislocations.
The observed data support age and articulation as potential factors for surgical planning: THA may improve implant durability in adolescents, while patients aged 12 years or younger remain at high revision risk regardless of articulation; this is an observational hypothesis requiring confirmation rather than evidence that one approach is universally superior.
A multidisciplinary UK workshop developed a strategic roadmap for trials in four rare pediatric CNS tumor groups, prioritizing coordinated data collection, international collaboration, and efficient designs such as platform, adaptive, Bayesian, and external-control approaches.
The record provides consensus-based support for trial-infrastructure and design strategies rather than evidence for a specific therapy; it is reasonable to infer that implementing these strategies could accelerate evaluation of treatments in very small pediatric CNS tumor populations, but no therapeutic efficacy, safety, or outcome improvement is demonstrated.
In a retrospective cohort of 41 children with Burkitt lymphoma, recurrent molecular alterations correlated with selected clinical features but not significantly with treatment response or prognosis, while plasma ctDNA in 19 patients showed high tissue concordance and cleared during therapy.
The evidence supports ctDNA as a candidate biomarker for molecular profiling and treatment-response monitoring in pediatric Burkitt lymphoma; it may eventually help tailor treatment intensity or detect inadequate response, but this clinical benefit is inferential and requires prospective validation because all 19 monitored patients survived and no actionable ctDNA threshold or comparative outcome benefit was demonstrated.
In a retrospective cohort of 37 pediatric patients with pilocytic astrocytoma, MRI-derived tumor growth velocity generally decreased after surgical resection, with the clearest reduction after a second resection in a 14-patient longitudinal subgroup.
The reported observations suggest that resection, including repeat resection, may be associated with slower subsequent growth of residual pediatric pilocytic astrocytoma; it is an inference—not established by this study—that validated growth-velocity measurements could help select patients for surgery or surveillance, because causality and clinical benefit were not assessed.
In a retrospective single-center cohort of 68 children with PRETEXT III–IV hepatoblastoma treated with neoadjuvant chemotherapy and definitive liver resection or transplantation, five-year survival was favorable overall, while recurrence—particularly pulmonary progression—and mortality were associated with limited alpha-fetoprotein decline and metastatic disease at diagnosis.
The study provides observational evidence that AFP trajectory, pulmonary response, and metastatic status are prognostic around definitive surgery; it is reasonable—but not proven—to hypothesize that prospectively integrating these factors into surgical planning and postoperative surveillance could improve treatment selection and earlier identification of high-risk children.
In a single-institution retrospective study of 88 children, adolescents, and young adults with high-grade osteosarcoma, high Area Deprivation Index was associated with longer prediagnosis symptom duration, more acute-care presentations, worse 5-year overall and local recurrence-free survival, and independently increased mortality risk, whereas several other social determinants did not identify survival differences.
The evidence supports ADI as a prognostic disparity marker in this cohort; as an inference requiring prospective validation, ADI-guided identification of patients for earlier diagnostic navigation or additional social and treatment support might reduce care barriers and potentially improve outcomes, but no intervention was tested.
